Jacobson Resonance Enterprises, Inc. Chairman Dr. Jerry I. Jacobson: `There Is Hope For Diabetic Neuropathy Sufferers'


BOYNTON BEACH, Fla., May 25, 2004 (PRIMEZONE) -- Jacobson Resonance Enterprises, Inc. (OTCBB:JRSE) announced encouraging news today for millions worldwide who suffer from Diabetic Neuropathy. One such recipient whose quality of life has been restored while being treated with Jacobson Resonance "Magnetic Resonance Therapy" in Nassau, New Providence, is Mr. Ehurd Cunningham F.C.C.A employed at the Ministry of Finance.

Mr. Cunningham shares: "My restoration healing has been like a miracle. Dr. Jacobson took time to explain to me what the treatment process entailed. This allowed me to have a high level of trust, confidence and faith in the process. I have progressed from a position of just barely able to wear slippers to now wearing my regular shoes everyday."

Mrs. Agatha Bellott, another diabetic neuropathy patient reports: "When I walked into the MRT Clinic I could hardly get around without my cane or walking stick. Now I can jump and also exercise on my own for at least one half hour non-stop. I thank God, and Dr. Jacobson and Harvey Grossman."

JRSE Chairman, Chief Executive Officer and Chief Science and Technology Officer Dr. Jerry I. Jacobson states: "The scientific base of Jacobson Resonance established by researchers and clinicians around the world is now solid and is rapaciously growing. Effects from magnetic fields naturally existing in human systems are astounding scientists as they witness the remarkable diversity of possibilities -- central theme and prediction of the theory for 25 years. Of course the most critical application of these low intensity, extremely low frequency magnetic fields is represented by the restoration of the quality of life for those suffering with relatively intractable illnesses. One such example refers to Diabetic Neuropathy.

"The foot of the diabetic is very susceptible to all forms of trauma. Clinical manifestations of diabetic neuropathy include sensory disturbances, plantar ulcers, trophic skin lesions, and autonomic neuropathy, (anhidrosis, vasodilation, edema, erythema, atrophy of skin and subcutaneous tissues). When infections occur, pyogenic organisms are often associated with a fungal infection, and may lead to ulcerations favoring secondary bacterial invasions. This may progress to cellulitis, lymphangitis, abscesses, osteomyelitis and gangrene.

"I have witnessed the benefits of using Jacobson Resonance (outside the USA) to treat diabetic neuropathy in various clinical facilities around the world, most recently in Nassau. The burning pain, stiffness and numbness that patients suffer have been consistently palliated with our non-invasive procedure. Although still anecdotal, from a scientific point of view, the Jacobson Resonator has clearly restored normalcy in many respects to the feet of those suffering from this dreaded illness."

The continued successes in restoring quality of life for our clients and patients in Nassau has short and long-term positive implications for the emerging business model of treatment centers outside the USA. With proper training and education we foresee that this model can be duplicated in the Caribbean Basin and indeed world-wide outside the United States.

JRSE is an emerging worldwide leader in magnetic resonance technology, whose main focus is the eradication of human suffering. The Company's technology base has the potential for multiple industry applications including the fields of healthcare, veterinary medicine, the leisure, spa, beauty and sports arenas, food and beverage, pharmaceuticals, energy and the environment.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The matters covered by such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements of the Company to differ materially from those contemplated or implied by such forward-looking statements. Included in these risks and other factors are funding availability, competition from better-financed companies and required regulatory clearances. For further information, contact Anthony P. Fusco, Jr. at (561) 752.4141.


            

Kontaktdaten